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Abstract
Background: The optimal resection extent for papillary thyroid microcarcinoma (PTMC) remains controversial. The
objective of the study was to investigate risk factors of bilateral PTMC and central lymph node metastasis (CLNM) to
guide surgical strategies for PTMC patients.
Methods: We retrospectively reviewed 211 PTMC patients who underwent total thyroidectomy (TT) and 122 clinical
lymph node-negative (cN0) cases that underwent prophylactic central lymph node dissection (CLND) between 2010
and 2011. The frequency, pattern, and predictive factors for bilateral PTMC and CLNM in these patients were studied
using univariate and multivariate analysis with respect to the following variables: age, gender, extrathyroidal
extension (ETE), T stage, with Hashimoto thyroiditis (HT), tumor size and multifocality based on final pathology, and
preoperative evaluation using ultrasonography (US).
Results: Fifty-four of 211 (25.6%) patients had bilateral PTMC. In multivariate analysis, multifocality (P<0.001,
OR=23.900) and tumor size ≥7m m( P=0.014, OR=2.398) based on US were independent predictive factors for
bilateral PTMC which was also independently associated with multifocality (P<0.001, OR=29.657) and tumor size
≥7m m( P=0.005, OR=2.863) based on final pathology. Among 122 cN0 patients who underwent prophylactic
CLND, we found 49.2% of patients had CLNM. CLNM was independently associated with men, age <50 years and
tumor size ≥7 mm based on final pathology or preoperative US.
Conclusions: TT should be considered for PTMC patients who are found multifocality and tumor size ≥7 mm based
on preoperative US. CLND need be considered in cN0 patients who are men, aged <50 years or tumor size ≥7m m
based on preoperative US.
Keywords: Papillary micro-carcinoma, Bilateral thyroid cancer, Multifocality, Thyroidectomy, Central lymph node
metastasis
Background
Thyroid cancer is the most frequent endocrine malig-
nancy, accounting for approximately 1% of all malignant
tumors in the United States [1] and 5.90% (with the inci-
dence of 21.76/100,000) in one district of Wenzhou (a
coastal city in Southeast China, with a referral popula-
tion of 7,558,000) [2]. Papillary thyroid carcinoma (PTC)
represents the most common type, with incidence
increasing each year, especially in papillary thyroid
microcarcinoma (PTMC) which is a type of PTC with a
maximum diameter of 1.0 cm or less [3]. Unfortunately
PTMC treatment is still controversial. While some doc-
tors believe that the observation is appropriate, most ad-
vocate surgical resection [4,5]. In general, TT or
therapeutic CLND should be performed when bilateral
lobe involvement or CLNM is preoperatively detected.
However, unilateral lobectomy may be applicable for
patients who have only found PTMC confined to the
unilateral lobe based on preoperative detection [6-8]. It
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ment was about 10–30% [9-11] and the rate of CLNM
could reach up to 61% [12]. Whether TT or CLND should
be offered to patients who could not detect bilateral lobe
involvement or CLNM preoperatively is still controversial.
So, how to predict PTMC with bilateral involvement or
CLNM is crucial for determining initial surgical resection.
In this study, we retrospectively examined the incidence
and related risk factors of PTMC with bilateral involve-
ment and CLNM, attempting to reveal the independent
predictors and hope to identify a subset of PTMC patients
who may benefit from TT or CLND in initial surgery.
Methods
This study was approved by the institutional review board
of the First Affiliated Hospital of Wenzhou Medical Col-
lege. A total of 211 cases of PTMC patients were initially
treated in our oncology department between 2010 and
2011. All patients had no history of neck irradiation and
underwent preoperative US and US-guided fine needle
aspiration biology (FNAB) whose diagnosis was PTC. TT
was routinely operated and ultimately diagnosed as
PTMC. Cases with accidental discovery of PTC and
patients who underwent completion of total thyroidect-
omy were not found in our series. All patients accepted
CLND routinely; apart from 89 patients whose preopera-
tive detection of suspicious neck lymph nodes, 122 cases
with cN0 who underwent prophylactic CLND were
included in the study of CLNM.
The following variables were used to analyze risk factors
of PTMC bilateral involvement and CLNM: gender, age at
diagnosis, final pathological primary tumor size and muli-
focality, extrathyroidal extension (ETE), with Hashimoto
thyroiditis (HT), primary tumor size and mulifocality
based on preoperative US. Final pathological PTMC bilat-
eral involvement and CLNM were examined as binary
variables. All pathological findings were confirmed by two
experienced endocrine pathologists and PTMC diagnosis
was defined as PTC whose maximum size is ≤1c m
according to World Health Organization standards. Bilat-
eral PTMC was diagnosed according to PTMC in both
sides of the thyroid gland which differed from unilateral
PTMC with foci in only one side lobe or isthmus. Mulifo-
cality was defined as more than one tumor lesion in the
primary tumor ipsilateral lobe. Tumor size in multifocal
PTMC patients was measured according to maximum
diameter of the primary tumor. Primary tumor size based
on preoperative US was measured by the standard of
change in echo edge. Preoperative mulifocality was defined
as more than one suspicious lesion in one side lobe
according to US findings. Suspicious lesions based on US
expressed as irregular shape, ill-defined margin, echogeni-
city, micro-calcification, or vascularity.
The results are expressed as the mean±SD. To com-
pare the differences, two-tailed student t test was used in
measurement data and chi-square test or Fisher exact
test was used in enumeration data, while Logistic regres-
sion multivariate analysis was used for further study. The
application of two-tailed test P value <0.05 was consid-
ered statistically significant. Statistical analysis was per-
formed using SPSS 18.0.
Results
A total of 211 patients consisted of 179 women and 32
men with a median age of 49±11 years (range, 23–79
years). The median size of the primary thyroid cancer
was 5.8±2.7 mm (1–10 mm). Mulifocality was found in
25 patients (11.8%) and HT was found in 59 patients.
ETE was found in 10 patients (4.7%), in which seven
cases were classified as T3 staging and three cases were
classified as T4 staging (Table 1). Of the 211 patients
with PTMC, 54 (25.6%) had bilateral disease, and 157
(74.4%) were unilateral PTMCs. Univariate analysis of
potential clinicopathologic factors associated with bilat-
eral PTMC is shown in Table 1. Contralateral PTMC
was significantly more frequent in patients with final
pathological multifocality (P <0.001) and primary tumor
size ≥5m mo r≥7m m( P=0.015, 0.018, respectively).
Table 1 Clinicopathological characteristics and univariate
analysis of 211 patients
Characteristics Total
(n=211)
Bilateral
PTMC (n=54)
Unilateral
PTMC (n=157)
P value
Gender(M/F) 32/179 8/46 24/133 0.934
Age±SD (years) 49±11 49±10 48±11 0.679
a
≥45/<45 143/68 38/16 105/52 0.636
≥50/<50 97/114 23/31 74/83 0.564
Primary
tumor size±SD (mm)
5.8±2.7 6.8±2.6 5.5±2.7 0.001
a,b
≥5/<5 144/67 44/10 100/57 0.015
b
≥7/<7 81/130 28/26 53/104 0.018
b
Multifocality (%) 25 (11.8) 21 (38.9) 4 (2.6) <0.001
b
ETE (%) 10 (4.7) 5 (9.3) 5 (3.2) 0.128
c
T stage (T1/2:T3/4) 201/10 49/5 152/5 0.128
c
With HT (%) 59 (28.0) 20 (37.0) 39 (24.8) 0.085
Preoperative
tumor size (mm)
6.1±2.9 7.1±2.7 5.8±2.8 0.005
a,b
≥5/<5 152/59 46/8 106/51 0.013
b
≥7/<7 85/126 29/25 56/101 0.020
b
Preoperative
multifocality (%)
19 (8.6) 16 (29.6) 3 (1.9) <0.001
b,c
aCalculated using two-tailed student t test.
bStatistically significant (P <0.05).
cCalculated using Fisher exact test, others calculated using chi-square test.
ETE, extrathyroidal extension; HT,Hashimoto thyroiditis; PTMC, papillary thyroid
microcarcinoma.
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ence of contralateral carcinoma and age, gender, ETE, T
stage and with HT. We also found the preoperative mul-
tifocality (P <0.001) and tumor size (≥5m mo r≥7 mm,
P=0.013, 0.020, respectively) which prompted by US
were associated with bilateral PTMC.
We conducted multivariate logistic regression analysis
of final pathological factors and preoperative factors sep-
arately. The results showed that tumor size ≥5m ma s
the size threshold was not an independent factor, whose
results of the analysis did not show. However, final
pathological multifocality (P <0.001, OR=29.657) and
primary tumor size ≥7m m( P=0.005, OR=2.869) still
showed a significant correlation with bilateral PTMC.
The same results were found in preoperative multifocal-
ity (P<0.001) and primary tumor size ≥7m m( P=0.014,
OR=2.398) which prompted by US. Table 2 shows the
results of logistic regression analysis.
Of 122 cN0 patients who underwent CLND, 60 cases
(49.2%) had CLNM. Univariate analysis of relevant clinico-
pathologic factors in association with CLNM is expressed
in Table 3. Apart from ETE, Tstage and with HT, others as
men (P=0.015), aged<50 years (P=0.011), final patho-
logical tumor size≥7m m( P=0.011), multifocality
(P=0.020), and bilateral PTMC (P=0.020) were signifi-
cantly related to CLNM. Similarly, preoperative tumor
size≥7 mm and multifocality which was promoted by US
were also significant differences between the central lymph
node positive and negative groups (P=0.001 and 0.027,
respectively).
However, further multivariate analysis showed that bi-
lateral PTMC did not enter the final logistic regression
equation (P=0.367) and multifocality was also a con-
founding factor (P=0.138). Interestingly, being male
(P=0.008, OR=4.848), aged <50 years (P=0.004, OR=
3.442), and the final pathological tumor size≥7m m
(P=0.011, OR=2.908) were independently associated
with CLNM. At the same time, logistic regression
analysis of preoperative factors also reached a similar re-
sult: males (P=0.008, OR=4.910), aged <50 years
(P=0.005, OR=3.311) and the preoperative tumor size≥
7m m( P=0.009, OR=2.964) based on US were inde-
pendent predictors of CLNM. Table 4 shows results of
logistic regression analysis using the significant risk fac-
tors in association with CLNM.
Discussion
PTMC will likely draw continued attention given its in-
creasing incidence in recent years. AlthoughTTand CLND
currently constitute the common initial surgical manage-
ment of patients with larger PTC, the best surgical extent
for PTMC is still a controversial topic [13]. When surgery
is performed for PTMC, it is generally accepted that TT or
CLND should be performed for preoperatively detected bi-
lateral PTMC or CLNM. However, the optimal extent of
surgical resection in cases with preoperatively undetected
bilateral PTMC or CLNM remains a topic of debate. We
retrospectively reviewed clinicopathological factors of
PTMC patients and found that primary tumor≥7m ma n d
multifocality were independent predictors of bilateral
PTMC, and being male, aged <50 years, and primary
tumor≥7 mm could be used to predict CLNM. Further,
multifocality and primary tumor≥7 mm could be
Table 2 Logistic regression analysis of the significant risk
factors in association with bilateral PTMC
Factors β S.E. P value OR value 95%CI
Final pathological factors
Tumor size
(≥7 mm/<7 mm)
1.054 0.378 0.005
a 2.869 1.366–6.023
Multifocality 3.390 0.601 <0.001
a 29.657 9.140–96.234
Constant −2.028 0.286
Preoperative factors
Preoperative tumor
size(≥ 7 mm/<7 mm)
0.875 0.357 0.014
a 2.398 1.192–4.824
Preoperative multifocality 3.174 0.668 <0.001
a 23.900 6.456–88.475
Constant −1.806 0.263
aStatistically significant (P <0.05).
Table 3 Clinicopathological characteristics and univariate
analysis of 122 cases of PTMC patients who underwent
prophylactic CLND
Characteristics Total
(n=122)
CLNM+
(n=60)
CLNM -
(n=62)
P
Value
Gender (M/F) 60/62 44/16 16/46 0.015
a
Age±SD (years) 48±11 46±10 50±11 0.044
a,b
≥45/<45 83/39 37/23 46/16 0.138
≥50/<50 57/65 21/39 36/26 0.011
a
Tumor size±SD (mm) 6.5±2.6 7.2±2.3 5.8±2.7 0.002
a,b
≥5/<5 95/27 51/9 44/18 0.062
≥7/<7 59/63 36/24 23/39 0.011
a
Multifocality (%) 19 (15.6) 14 (23.3) 5 (8.1) 0.020
a
ETE (%) 7 (5.7) 5 (8.3) 2 (3.2) 0.269
c
T stage (T1/2:T3/4) 115/7 55/5 60/2 0.269
c
With HT (%) 43 (35.2) 19 (31.7) 24 (38.7) 0.416
Bilateral PTMC (%) 60 (50.8) 26 (61.9) 34 (42.5) 0.042
a
Preoperative tumor
size (mm)
6.8±2.8 7.5±2.6 6.1±2.9 0.008
a
≥5/<5 99/23 52/8 47/15 0.125
≥7/<7 61/61 37/23 24/38 0.001
a
Preoperative multifocality (%) 16(13.1) 12(20.0) 4(6.6) 0.027
a
a Statistically significant (P<0.05).
bCalculated using two-tailed student t test.
cCalculated using Fisher exact test, others calculated using chi-square test.
CLNM, central lymph node metastasis; ETE, extrathyroidal extension; HT,
Hashimoto thyroiditis; PTMC, papillary thyroid microcarcinoma.
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who need TT or CLNM.
Surgeons who advocated TT believed that thyroid can-
cer often presented in both sides of thyroid lobes. Then,
how many cases had bilateral involvement in thyroid can-
cer patients? Studies had reported that the rate of bilateral
PTC ranged from13% to 56% that could be found in com-
pletion thyroidectomy and TT [14-17] and incidence of bi-
lateral PTMC was approximately 10–30% in PTMC
patients [9-11,17,18]. In our study, 25.6% of PTMC
patients who underwent TT had contralateral PTMC. This
rate was consistent with the previous reports [9-11,17,18].
In our opinion, a 25.6% ratio for a contralateral carcinoma
does not justify routine TT for all PTMC patients. Multifo-
cality had been prompted as a predictor of contralateral
thyroid cancer in a number of studies [14,15,19,20]. Our
study confirmed the predictive value of multifocality and
found that 84% of multifocal PTMC patients had contra-
lateral lobe foci, which may be due to that bilateral PTMC
often arise from a single clone and intrathyroidal metasta-
sis [21]. Primary tumor size in the previous study was con-
sidered to be nothing to do with the contralateral PTC
[15,20,22-24]. However, our study found that bilateral
PTMC may be more vulnerable to have a large primary
tumor (≥ 5m m / ≥ 7 mm), and primary tumor≥7m mw a s
an independent predictor of contralateral lobe PTMC. A
reason inconsistent results may be attributed to our re-
search was a retrospective study and the object was PTMC
patents who underwent TT, compared to the previous pro-
spective study [22] and patients with clinical unilateral
PTMC [20]. Moreover, the number of PTMC cases in our
study increased compared to the study of Pitt et al. [15]
and we firstly used a tumor size >7 mm as the size thresh-
old in study of bilateral PTMC. In addition, previous stud-
ies had reported that bilateral PTC was inter-related with
advanced Tstage and high incidence of ETE [16,23]. How-
ever, we did not obtain the same results in PTMC cases
agreed with previous studies of bilateral PTMC [20,22].
The reasons may be attributed to that PTMC was found
early and micro-foci, which may not yet demonstrate full
biological behavior. Others such as gender, age, and with
HT were not found significant difference as other papers
reported [20,22,24].
Therapeutic CLND in PTMC patients is always neces-
sary, whereas prophylactic CLND remains a subject of
considerable debate. The 2009 guidelines of the Ameri-
can Thyroid Association (ATA) recommend prophylactic
CLND in patients with cN0 PTCs, particularly in those
with advanced T3 and T4 primary tumors, but do not
recommend elective central neck dissection in patients
with small, non-invasive cN0 PTCs [25]. A high inci-
dence of CLNM in PTMC patients has been reported
(up to 61%) [12]. Our study found the CLNM rate was
49.2% in PTMC patients with preoperatively undetected
CLNM. Although US has been regarded as a sensitive
imaging modality for thyroid screening and diagnosis,
US has a low sensitivity in evaluation of metastasis in
CLNM [26]. Similarly, in our study, imaging studies were
not useful in the detection of CLNM. Age is known to
be an important prognostic factor for patients with PTC
greater than 1 cm; however, its prognostic value in
PTMC was uncertain [12,27-29]. Most studies used an
age <45 years as the age threshold [30,31]. In our study,
age <50 years was found to be independently associated
with the greatest risk of CLNM, but an age <45 years as
the age threshold may be too small to assess the CLNM.
In addition, consistent with previous reports, we also
found that being male was an independent risk factor of
CLNM. Previous studies have suggested that CLNM was
associated with tumor size [12,32,33]. Most studies used
a tumor size >5 mm as the size threshold. Lee et al.
thought that a cutoff value of 7 mm may be considered
the threshold of aggressiveness of PTMCs [34]. Our ana-
lysis found that tumor size≥7 mm was independently
associated with CLNM, but a threshold >5 mm may be
too small to assess the CLNM. We also revealed pre-
operative tumor size≥7 mm based on US could be used
to predict CLNM. Thus, preoperative tumor size≥7m m
based on US, combined with being male and aged<50
years can be used to predict the CLNM, and guide
CLND. In our study, we found that cases who had bilat-
eral PTMC and multifocality may be prone to CLNM
(P=0.042 and 0.020, respectively), but they were not in-
dependent risk factors. In addition, disagreeing with a
previous report [28], our study did not prompt that
Table 4 Logistic regression analysis of the significant risk
factors in association with CLNM
Factors β S.E. P value OR value 95%CI
Final pathological factors
Gender (M/F) 1.578 0.592 0.008
a 4.848 1.519–15.466
Age (<50y/≥50y) 1.236 0.428 0.004
a 3.442 1.488–7.963
Tumor size
(≥7 mm/<7 mm)
1.067 0.419 0.011
a 2.908 1.278–6.614
Multifocality 0.991 0.667 0.138 2.693 0.728–9.956
Bilateral PTMC 0.436 0.484 0.367 1.547 0.600–3.993
Constant −1.787 0.448
Preoperative factors
Gender (M/F) 1.591 0.596 0.008
a 4.910 1.526–15.796
Age (<50y/≥50y) 1.199 0.424 0.005
a 3.311 1.443–7.634
Preoperative tumor size
(≥ 7 mm/<7 mm)
1.086 0.418 0.009
a 2.964 1.305–6.729
Preoperative multifocality 0.806 0.706 0.253 2.240 0.562–8.931
Bilateral PTMC 0.584 0.466 0.210 1.793 0.719–4.469
Constant −0.600 0.371
aStatistically significant (P<0.05).
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may be due to our low rate of ETE which was not
included microscopic extension.
Although our analysis is limited because of the lack of
both long-term follow-up results and prognostic implica-
tion of bilateral PTMC and CLNM, we did highlight the
predictive value of preoperative primary tumors≥7m m
and multifocality both prompted by US, which can be con-
tributed to compensate for the lack of preoperative sensitiv-
ity to reveal undetected bilateral PTMC and CLNM.
Conclusions
Of all PTMC patients who underwent TT, 25.6% had bilat-
eral PTMC. Tumor size≥7 mm and at least one multifocal
lobe were independent risk factors for bilateral PTMC and
both can be prompted by US to guide TT. The rate of
CLNM was 49.1% in cN0 patients. Factors such as tumor
foci ≥7 mm based on final pathology or US, being male,
and a younger age (<50 years) can be used to predict CLN
metastasis. Surgeons are justified to offer TT to PTMC
patients with multifocality and foci ≥7 mm based on pre-
operative US. CLND needs to be considered in PTMC
patients who are men, aged<50 years, or foci ≥7m m
based on preoperative US.
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